(State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) | ||||||||||||
(Address of principal executive offices) | (Zip Code) |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a–12 under the Exchange Act (17 CFR 240.14a–12) |
Pre–commencement communications pursuant to Rule 14d–2(b) under the Exchange Act (17 CFR 240.14d–2(b)) |
Pre–commencement communications pursuant to Rule 13e–4(c) under the Exchange Act (17 CFR 240.13e–4(c)) |
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Sesen Bio, Inc. | ||||||||
By: | /s/ Thomas R. Cannell, D.V.M. | |||||||
Thomas R. Cannell, D.V.M. | ||||||||
President and Chief Executive Officer |
Cover |
Sep. 29, 2022 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Entity Registrant Name | SESEN BIO, INC. |
Entity Incorporation, State or Country Code | DE |
Entity File Number | 001-36296 |
Entity Tax Identification Number | 26-2025616 |
Entity Address, Address Line One | 245 First Street |
Entity Address, Address Line Two | Suite 1800 |
Entity Address, City or Town | Cambridge |
Entity Address, State or Province | MA |
Entity Address, Postal Zip Code | 02142 |
City Area Code | 617 |
Local Phone Number | 444-8550 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock, par value $0.001 |
Trading Symbol | SESN |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
Entity Central Index Key | 0001485003 |
Amendment Flag | false |
Document Period End Date | Sep. 29, 2022 |
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end
!&><)'AOLBZW[_;!4EWP>-2"^D"*;D$
M+$J#>QG%C&D >RD0NT^SBS!L6$
M"Y5;DG5:NL'_&@V1H.:4>./<.A.^>]F&> 4?'
MO$6;O!H7_*>L#F-@PE7'T5).HMKX9H/U*J/\W[JZ;,_RXG;NRNME"E)):20X
M122(& D812@HG<7BS$C.QRT%?V)\V&-4DZ\WCA=V$GP<9LEJMS[*6YRK_^'U
MDG*NM0LN YXS)D$2!ZMSVNQ(9"H1&B7;1B'Z@=EA3$RX!#E>S!>FX2#O=V.W
MYWV[=JLET]01GWUVC-@L0V;9AJQ*'HU4*6=,"<<]7WG/W+#H3[@*^7SQ7CCJ
M=P\%GV!=5/%-&7]R+2ZY)U;G1 94]!RZ.R7@\]X65(C>>&9,2')4])\T.XR"
M"9<@QXNY-1I>+1Z)>)P;]G=NO^A>NC]*[._\'U!+ 0(4 Q0 ( A /54Z
MWJ<#,!@ *.@ 1 " 0 !S97-N+3(P,C(P.3(Y+FAT
M;5!+ 0(4 Q0 ( A /55HXT?+:0( &X' 1 " 5\8
M !S97-N+3(P,C(P.3(Y+GAS9%!+ 0(4 Q0 ( A /56YE$3;E@H !%A
M 5 " ?<: !S97-N+3(P,C(P.3(Y7VQA8BYX;6Q02P$"
M% ,4 " (0#U5:Q!W8\\& #V,@ %0 @ ' )0